Condition
Acute Promyelocytic Leukaemia
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 3 (3)
Trial Status
Unknown1
Not Yet Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07504458Phase 3Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07296445Phase 3Not Yet Recruiting
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
NCT04175587Phase 3UnknownPrimary
Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
Showing all 3 trials